-+ 0.00%
-+ 0.00%
-+ 0.00%

Provectus ophthalmology unit VisiRose to present RB-PDAT at ESCRS iNovation Day 2026 showcase

PUBT·07/22/2026 12:02:57
Listen to the news
Provectus ophthalmology unit VisiRose to present RB-PDAT at ESCRS iNovation Day 2026 showcase
  • VisiRose, Provectus Biopharmaceuticals’ clinical-stage ophthalmology subsidiary, was selected to present RB-PDAT at ESCRS iNovation Day 2026 in London.
  • Showcase slot targets infectious keratitis, positioning RB-PDAT as a broad-spectrum photodynamic antimicrobial designed to avoid drug-resistance pathways.
  • RB-PDAT pairs rose bengal sodium with green-light activation to generate reactive oxygen species intended to inactivate pathogens on the cornea.
  • Clinical track record cited includes 280+ treated patients; REAGIR Phase 3 missed its primary endpoint versus natamycin in the overall population.
  • Company estimates the global market for rose bengal sodium-based ophthalmic therapies at more than USD 20 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220800PRIMZONEFULLFEED9765949) on July 22, 2026, and is solely responsible for the information contained therein.